Small molecule drugs for atopic dermatitis, rheumatoid arthritis, and hereditary angioedema
- 1 March 2022
- journal article
- review article
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 128 (3) , 263-268
Abstract
No abstract availableKeywords
Funding Information
- Takeda Pharmaceutical Company
- BioCryst
- GlaxoSmithKline
- CSL Behring
This publication has 40 references indexed in Scilit:
- Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseasesWorld Journal of Gastroenterology, 2018
- Emerging Treatment Options in Atopic Dermatitis: Topical TherapiesDermatology, 2017
- Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseasesJournal of Autoimmunity, 2017
- A clinical pathway for the management of difficult venous accessBMC Nursing, 2017
- Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitisJournal of the American Academy of Dermatology, 2017
- Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitisBMC Pediatrics, 2016
- Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedsideThe Journal of Biochemistry, 2015
- Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspectivePatient Preference and Adherence, 2015
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014
- C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks - final results of the I.M.P.A.C.T.2 studyAllergy, 2011